Connecting RNAi Leaders Worldwide To Showcase Breakthroughs, Spark Partnerships and Aaccelerate Innovation
The 7th RNAi-Based Therapeutics Summit returns to Boston on January 27-29, 2026, uniting 80+ senior leaders from top pharma, innovative biotechs, and investment firms. As the industry’s premier forum for RNAi, this event is designed to tackle the most pressing challenges in translating siRNA and miRNA drugs beyond the liver.
Through deep engagement with the RNAi community, we’ve identified their critical pain points, including:
- Achieving targeted extrahepatic delivery to CNS, muscle, adipose, and renal tissues
- Overcoming complex CMC, synthesis, and regulatory hurdles for novel modalities
- Leveraging AI and data-driven approaches for novel target discovery and validation
- De-risking clinical pathways for neurological, metabolic, and oncological diseases
Partner with us in 2026 to elevate your brand and secure direct access to our audience of senior decision-makers from companies like Alnylam, Biogen, AbbVie, and SaneGene Bio all actively investing in the next wave of RNAi therapeutics.

What the Summit Delivers for Partners
Distinguish Your Solutions
Stand out by demonstrating your expertise in overcoming the unique hurdles of RNAi therapeutic development:
- Advanced Delivery Platforms: Showcase work in targeted conjugates, LNPs, exosomes, or novel modalities (e.g., DNA origami, AOCs) for precise tissue targeting.
- CMC & Manufacturing Excellence: Highlight capabilities in oligonucleotide synthesis, LNP formulation, and analytical development to ensure purity and regulatory compliance.
- AI-Driven Discovery: Demonstrate computational tools for target validation, predicting off-target effects, and designing next-generation RNAi structures.
Generate Commercial Opportunities
The 7th RNAi-Based Therapeutics Summit’s intentionally curated forum fosters high-value connections between solution providers and the RNAi leaders who need them most. With attendance capped to maintain an intimate environment, you’ll engage in meaningful dialogues with executives from clinical-stage biotechs like Gensaic, leveraging AI-designed ligands for muscle targeting, and Judo Biosciences, pioneering kidney-targeted silencing with their STRIKE™ platform, along with BD and R&D teams from Alnylam, Biogen, and AbbVie attending to identify partners who can de-risk their path to the clinic and beyond.
Raise Your Brand Awareness
Showcase your solutions to the key opinion leaders and decision-makers who rely on specialized partners to solve critical challenges in extrahepatic delivery, novel chemistries, and scalable manufacturing.
Powering innovation in RNAi-Based Development
Our attendees from 80+ leading biopharma companies, innovative biotechs, and top academic institutions are actively seeking partners with specialized expertise to overcome the field’s most pressing challenges, from extrahepatic delivery to late-stage CMC and clinical translation. Whether you specialize in novel delivery platforms, oligonucleotide synthesis, AI-driven discovery, or translational models for non-liver tissues, partnering with the 7th RNAi-Based Therapeutics Summit connects you directly with senior decision-makers scouting solutions to:
- Achieve targeted delivery beyond the liver to CNS, muscle, and adipose tissue
- Overcome complex CMC and manufacturing hurdles for novel conjugates and modalities
- Leverage AI and computational tools for target validation and reducing off-target effect
- De-risk clinical translation for neurological, metabolic, and rare diseases

Key Interest Areas
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque facilisis leo risus, sed molestie eros cursus id. Integer hendrerit tincidunt bibendum. Mauris molestie ex sed ante egestas, ac tincidunt diam dapibus.
Raw Materials: Oligonucleotide & RNAi Synthesis, Reagents & Assay
With the complexity of RNAi chemistries and modifications increasing, attendees urgently need high purity starting materials and specialized reagents.
Your phosphoramidites, custom nucleotides, enzymes, and nuclease-free assays are critical to bridge the gap by enabling the efficient synthesis, stabilization, and functional validation of novel siRNA and miRNA constructs.
Characterization & Bioanalytical Services
Advanced analytical equipment and services that assess identity, purity, strength, and structure are paramount for regulatory compliance and ensuring therapeutic efficacy.
Your LC/MS, SEC, and other physicochemical characterization tools help developers quantify payload integrity, impurity profiles, and stability, critical for IND filing and overcoming CMC hurdles for complex conjugates.
CDMO Services (CMC & Manufacturing, Fill/Finish)
CDMOs provide the operational expertise needed to navigate the complex synthesis, purification, and scale-up of novel RNAi modalities.
As developers like Alynlyam and Arrowhead advance candidates with intricate chemistries, they seek CDMO partners who understand the unqiue challenges of oligonucleotide manufacturing, lipid nanoparticle formulation, and aseptic fill/finish to ensure a smooth path from the clinic to commercial supply.
Single-cell RNA sequencing & Multi-Omics
Single-cell and multi-omics services provide unprecedented resolution into drug mechanism of action and off-target effects.
Your platforms help developers uncover heterogeneity in target gene knockdown, validate tissue-specific delivery, and identify novel biomarkers within complex tissues, critical for de-risking preclinical candidates and demonstrating compelling proof-of-concept to investors and partners
Attending Companies Include









Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.

Hannah Martin
Business Development Manager
Tel: +1 617 455 4188